Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04AMD
|
|||
| Former ID |
DIB013123
|
|||
| Drug Name |
ZD-6126
|
|||
| Synonyms |
219923-05-4; ZD6126; ZD-6126; UNII-GBO3S6M9W7; GBO3S6M9W7; N-Acetylcochinol-O-phosphate; AZD-6126; N-Acetylcolchicinol dihydrogenphosphate; ZD 6126; SCHEMBL1285000; CHEMBL257662; ANG 453; AZD6126, ANG453; ZINC3993833; AZD 6126; BCP9000366; DB11872; BCP0726000110; ZM 445526; Acetamide, N-((5S)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo(a,c)cyclohepten-5-yl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Angiogene Pharmaceuticals Ltd; Angiogene
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H24NO8P
|
|||
| Canonical SMILES |
CC(=O)NC1CCC2=CC(=C(C(=C2C3=C1C=C(C=C3)OP(=O)(O)O)OC)OC)OC
|
|||
| InChI |
1S/C20H24NO8P/c1-11(22)21-16-8-5-12-9-17(26-2)19(27-3)20(28-4)18(12)14-7-6-13(10-15(14)16)29-30(23,24)25/h6-7,9-10,16H,5,8H2,1-4H3,(H,21,22)(H2,23,24,25)/t16-/m0/s1
|
|||
| InChIKey |
UGBMEXLBFDAOGL-INIZCTEOSA-N
|
|||
| CAS Number |
CAS 219923-05-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin beta (TUBB) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00065572) Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV). U.S. National Institutes ofHealth. | |||
| REF 2 | Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.